Next Article in Journal
Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
Next Article in Special Issue
Merkel Cell Carcinoma: New Trends
Previous Article in Journal
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing
Previous Article in Special Issue
Regenerative Wound Dressings for Skin Cancer
Article

Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye

1
Department of Brachytherapy, St. John’s Cancer Center, 20-090 Lublin, Poland
2
Department of Radiotherapy, Medical University of Lublin, 20-093 Lublin, Poland
3
Department of Radiotherapy, St. John’s Cancer Center, 20-090 Lublin, Poland
4
Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland
5
Department of Clinical Immunology, St. John’s Cancer Center, 20-090 Lublin, Poland
6
Institute of Biology, University of Szczecin, Felczaka 3c, 71-412 Szczecin, Poland
7
I Department of Clinical Oncology, St. John’s Cancer Center, 20-090 Lublin, Poland
8
Department of Applied Psychology, Medical University of Lublin, 20-093 Lublin, Poland
*
Authors to whom correspondence should be addressed.
Academic Editor: Girish M. Shah
Cancers 2021, 13(6), 1425; https://doi.org/10.3390/cancers13061425
Received: 21 February 2021 / Revised: 12 March 2021 / Accepted: 16 March 2021 / Published: 20 March 2021
(This article belongs to the Special Issue Prevention, Diagnosis and Treatment of Skin Cancer)
Eyelid tumors account for approximately 3% of all head and neck cancers and 5 to 10% of all skin cancers. Among the basic methods of treating eyelid tumors, apart from surgery, is radiotherapy, but this method carries a high risk of complications within the eye lens and may lead to the development of cataracts. Interstitial HDR brachytherapy is a less invasive method of skin cancer treatment. Unfortunately, the analysis of the literature to date has shown that it is rarely used in the treatment of skin cancer in this location. In our study, we analyzed the results of 28 patients treated with HDR interstitial brachytherapy. We showed that this is a highly effective, short-lived and relatively low burden method of treating patients with neoplasms of the skin of the eyelids, medial and lateral angles, and skin cancer of the cheek, nose and temples with an infiltration of the ocular structures.
Background: Eyelid tumors are rare skin cancers, the most common of which is basal cell carcinoma characterized primarily by local growth. In addition to surgery, radiotherapy is among the basic methods of treatment. External beam radiotherapy is associated with the risk of complications within ocular structures, especially the lens. In the case of interstitial brachytherapy, it is possible to administer a high dose to the clinical target volume (CTV), while reducing it in the most sensitive structures. Methods: This paper presents the results of an analysis of 28 patients treated with interstitial high dose rate (HDR) brachytherapy for skin cancers of the upper and lower eyelid; medial and lateral canthus; and the cheek, nose and temples with the infiltration of ocular structures. The patients were treated according to two irradiation schedules: 49 Gy in 14 fractions of 3.5 Gy twice a day for 7 days of treatment, and 45 Gy in 5 Gy fractions twice a day for 5 days. The mean follow-up was 22 months (3–49 months). Results: two patients (6%) had a relapse: a local recurrence within the irradiated area in one of them, and metastases to lymph nodes in the other. The most common early complication was conjunctivitis (74%), and the most common late complication was dry eye syndrome (59%). Conclusions: Interstitial HDR brachytherapy for skin cancers of the upper and lower eyelid; medial and lateral cants; and the cheek, nose and temples with infiltration of ocular structures is a highly effective, short and relatively low burden type of treatment. View Full-Text
Keywords: HDR brachytherapy; non-melanocytic skin cancer; cancer around the eye; radiation therapy HDR brachytherapy; non-melanocytic skin cancer; cancer around the eye; radiation therapy
Show Figures

Figure 1

MDPI and ACS Style

Cisek, P.; Kieszko, D.; Bilski, M.; Dębicki, R.; Grywalska, E.; Hrynkiewicz, R.; Bębnowska, D.; Kordzińska-Cisek, I.; Rolińska, A.; Niedźwiedzka-Rystwej, P.; Grzybowska-Szatkowska, L. Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye. Cancers 2021, 13, 1425. https://doi.org/10.3390/cancers13061425

AMA Style

Cisek P, Kieszko D, Bilski M, Dębicki R, Grywalska E, Hrynkiewicz R, Bębnowska D, Kordzińska-Cisek I, Rolińska A, Niedźwiedzka-Rystwej P, Grzybowska-Szatkowska L. Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye. Cancers. 2021; 13(6):1425. https://doi.org/10.3390/cancers13061425

Chicago/Turabian Style

Cisek, Paweł, Dariusz Kieszko, Mateusz Bilski, Radomir Dębicki, Ewelina Grywalska, Rafał Hrynkiewicz, Dominika Bębnowska, Izabela Kordzińska-Cisek, Agnieszka Rolińska, Paulina Niedźwiedzka-Rystwej, and Ludmiła Grzybowska-Szatkowska. 2021. "Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye" Cancers 13, no. 6: 1425. https://doi.org/10.3390/cancers13061425

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop